1. U.S. Food and Drug Administration. Press Announcements - FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm589467.htm
. Accessed 5 May 2018.
2. Sangonowsky E Spark sets off gene therapy debate with $850K sticker on Luxturna | FiercePharma. FiercePharma. /pharma/spark-prices-gene-therapy-luxturna-at-850k-grabbing-top-spot-pharma-s-costliest-drugs. Published 3 January 3, 2018. Accessed 25 January2018.
3. NICE. Evaluation Consultation Document: Strimvelis for Treating Adenosine Deaminase Deficiency–Severe Combined Immunodeficiency.; 2017.
https://www.nice.org.uk/guidance/GID-HST10005/documents/evaluation-consultation-document
. Accessed October 25, 2017.
4. Touchot N, Flume M. Early Insights from Commercialization of Gene Therapies in Europe. Genes. 2017;8:78.
5. SEC Filings | Investors & Media | Spark Therapeutics.
http://ir.sparktx.com/phoenix.zhtml?c=253900&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTEwMTcwNDk3JkRTRVE9MSZTRVE9MTQmU1FERVNDPVNFQ1RJT05fUEFHRSZleHA9JnN1YnNpZD01Nw%3D%3D
. Accessed 25 October 2017.